Matthew L. Romo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthew L. Romo has a total of 305 co-authors. Here are the top co-authors by number of shared publications:
- Arturo Carpio
University of Cuenca
15 shared publications - Elizabeth A. Kelvin
CUNY Institute for Implementation Science in Population Health, City University of New York, New York, NY, USA
14 shared publications - Kaymarlin Govender
Health Economics and HIV/AIDS Research Division, University of KwaZulu Natal, Durban, South Africa
7 shared publications - Agnès Fleury
Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico; Unidad Periférica del Instituto de Investigaciones Biomédicas en el Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, Mexico
6 shared publications Eva Mwai
Department of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, City University of New York, New York, NY, United States
6 shared publications- Molly Forrest Franke
Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA
6 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Sociedad Latinoamericana de Nutricion in Archivos Latinoamericanos de Nutrición
- Vol. 66 (3) , 230-238
Differences in nutritional status, physical activity, and fruit and vegetable consumption in urban and rural school-going adolescents in Paute, Ecuador
Ecuador is undergoing a nutrition transition where overweight/obesity coexist with undernutrition. The objective of this study was to determine nutritional status, physical activity, fruit and vegetables consumption frequency among school-going adolescents in the canton of Paute and further explore if these variables were differential by urban vs. rural residence. We conducted a cross-sectional study using a random sample of students aged 12 to 19 years from the only two public secondary schools in the canton Paute. We determined nutritional status according to the World Health Organization criteria. Demographics, physical activity habits, fruit and vegetable consumption frequency were determined by questionnaires. Of the total of 314 students, 44.9% lived in urban area and 55.1% in rural area. The prevalence of overweight/obesity was significantly higher among students with urban vs. rural residence (28.4% vs. 17.9%; P=.03). The prevalence of stunting was significantly higher among students with rural vs. urban residence (31.8% vs. 16.3%; P=.002). There were no significant differences detected between groups in the frequency of consumption of fruits and vegetables. Urban residence was associated with a greater mean number of minutes of outdoor recreation after school (76.0 minutes vs. 57.1 minutes; P=.02), greater weekly hours of planned physical activity (2.0 hours vs. 1.6 hours; P=.007), and greater daily screen time in front of a television or computer (3.2 hours vs. 2.5 hours; P<.001). Interventions to prevent or reduce overweight/obesity in Paute and other similar areas with students from both urban and rural areas should consider place of residence in their design.
- 20 October 2026
- Published by Sociedad Latinoamericana de Nutricion in Archivos Latinoamericanos de Nutrición
- Vol. 66 (3) , 230-238
Open AccessDifferences in nutritional status, physical activity, and fruit and vegetable consumption in urban and rural school-going adolescents in Paute, Ecuador
Ecuador is undergoing a nutrition transition where overweight/obesity coexist with undernutrition. The objective of this study was to determine nutritional status, physical activity, fruit and vegetables consumption frequency among school-going adolescents in the canton of Paute and further explore if these variables were differential by urban vs. rural residence. We conducted a cross-sectional study using a random sample of students aged 12 to 19 years from the only two public secondary schools in the canton Paute. We determined nutritional status according to the World Health Organization criteria. Demographics, physical activity habits, fruit and vegetable consumption frequency were determined by questionnaires. Of the total of 314 students, 44.9% lived in urban area and 55.1% in rural area. The prevalence of overweight/obesity was significantly higher among students with urban vs. rural residence (28.4% vs. 17.9%; P=.03). The prevalence of stunting was significantly higher among students with rural vs. urban residence (31.8% vs. 16.3%; P=.002). There were no significant differences detected between groups in the frequency of consumption of fruits and vegetables. Urban residence was associated with a greater mean number of minutes of outdoor recreation after school (76.0 minutes vs. 57.1 minutes; P=.02), greater weekly hours of planned physical activity (2.0 hours vs. 1.6 hours; P=.007), and greater daily screen time in front of a television or computer (3.2 hours vs. 2.5 hours; P<.001). Interventions to prevent or reduce overweight/obesity in Paute and other similar areas with students from both urban and rural areas should consider place of residence in their design.
- Open Access
- 17 October 2026
- Published by Springer Nature in Nature Communications
Baseline radiographic and microbiologic predictors of treatment outcomes in a shortened all-oral regimen for MDR/RR-TB
WHO-endorsed shortened, all-oral regimens have improved tolerability and outcomes for MDR/RR-TB treatment, but predictors of poor outcomes remain incompletely-characterized. We conducted a prospective cohort study (NCT05871489) of adults with bacteriologically-confirmed pulmonary MDR/RR-TB treated with a shortened, all-oral regimen in Lesotho. We evaluated baseline microbiologic and radiographic features and their associations with time-to-culture-conversion, end-of-treatment outcomes, and final post-treatment outcomes. Among 238 participants (median age 41 [IQR:31–56], 29% female, 62% with HIV), there were 27 unfavorable outcomes (20 deaths, 3 treatment failures, 4 recurrences). 142 of 148 (95.9%) with positive baseline cultures experienced conversion within four months. Fibrosis, cavitation, bilateral disease, and high smear grade were associated with delayed culture conversion and lower odds of treatment success. Bilateral disease was more strongly associated with unfavorable outcomes in those without HIV; fibrosis and high smear grade showed stronger associations among those with HIV. Cavitation with high smear grade (uOR=0.29, 95%CI:0.11–0.78; aOR=0.39, 95%CI:0.14-1.14), and severe fibrocavitary disease (multi-lobar fibrosis and at least one cavity ≥5 cm) (uOR=0.20, 95%CI:0.07–0.64; aOR=0.26, 95%CI:0.07-0.94) were negatively associated with favorable final outcomes. These findings suggest that baseline sputum and chest radiographic features—particularly in-combination—identify higher-risk patients and may inform risk-adapted strategies for shortened all-oral MDR/RR-TB regimens.
- 17 October 2026
- Published by Springer Nature in Nature Communications
Open AccessBaseline radiographic and microbiologic predictors of treatment outcomes in a shortened all-oral regimen for MDR/RR-TB
WHO-endorsed shortened, all-oral regimens have improved tolerability and outcomes for MDR/RR-TB treatment, but predictors of poor outcomes remain incompletely-characterized. We conducted a prospective cohort study (NCT05871489) of adults with bacteriologically-confirmed pulmonary MDR/RR-TB treated with a shortened, all-oral regimen in Lesotho. We evaluated baseline microbiologic and radiographic features and their associations with time-to-culture-conversion, end-of-treatment outcomes, and final post-treatment outcomes. Among 238 participants (median age 41 [IQR:31–56], 29% female, 62% with HIV), there were 27 unfavorable outcomes (20 deaths, 3 treatment failures, 4 recurrences). 142 of 148 (95.9%) with positive baseline cultures experienced conversion within four months. Fibrosis, cavitation, bilateral disease, and high smear grade were associated with delayed culture conversion and lower odds of treatment success. Bilateral disease was more strongly associated with unfavorable outcomes in those without HIV; fibrosis and high smear grade showed stronger associations among those with HIV. Cavitation with high smear grade (uOR=0.29, 95%CI:0.11–0.78; aOR=0.39, 95%CI:0.14-1.14), and severe fibrocavitary disease (multi-lobar fibrosis and at least one cavity ≥5 cm) (uOR=0.20, 95%CI:0.07–0.64; aOR=0.26, 95%CI:0.07-0.94) were negatively associated with favorable final outcomes. These findings suggest that baseline sputum and chest radiographic features—particularly in-combination—identify higher-risk patients and may inform risk-adapted strategies for shortened all-oral MDR/RR-TB regimens.
- Open Access
- 1 September 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (5) , dlag215
Promethazine use and QT prolongation risk during treatment with a shortened all-oral regimen for MDR/RR-TB
Background: Shortened all-oral regimens for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) combine multiple QTc prolonging agents, including bedaquiline and delamanid, which act partly through hERG potassium channel binding. Promethazine, a first-generation antihistamine used for nausea during TB therapy, shares this mechanism. Whether adjunctive promethazine further raises the risk of clinically relevant QTc prolongation in this setting is unclear. Methods: We conducted secondary analyses from a prospective observational cohort study of patients ≥15 years in Lesotho who received a 9- to 12-month all-oral regimen (bedaquiline, linezolid, levofloxacin, clofazimine, delamanid) for pulmonary MDR/RR-TB. We modelled time-varying promethazine exposure using the Andersen-Gill formulation of Cox regression, with time-to-first grade ≥3 (>500 ms) QTc event as the outcome of interest. We conducted comparator analyses with time-varying exposure to metoclopramide, ondansetron, and episodes of nausea, dizziness, and vomiting. Results: Among 247 participants (median age 41, 63.2% living with HIV), 62 (25.1%) received promethazine. Grade ≥3 QTc prolongation occurred in 10 (4.0%). Incident clinically significant QTc prolongation was higher during promethazine-exposed than unexposed periods (7.4 versus 1.3 per 10 000 person-days; HR 7.0, 95% CI: 1.4–35.3). No comparable elevation was seen in analyses of exposure to metoclopramide (HR 1.0, 95% CI: 0.3–3.6), ondansetron, or episodes of nausea, dizziness, or vomiting (HR 1.5, 95% CI: 0.3–6.9). Conclusions: Promethazine use was associated with increased risk of clinically relevant QTc prolongation within a QTc-burdened all-oral MDR/RR-TB regimen. These findings provide preliminary evidence that clinicians may consider when selecting anti-emetics as part of MDR/RR-TB therapy with a shortened all-oral regimen and highlight the importance of evaluating adjunctive medications in DR-TB care.
- 1 September 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (5) , dlag215
Open AccessPromethazine use and QT prolongation risk during treatment with a shortened all-oral regimen for MDR/RR-TB
Background: Shortened all-oral regimens for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) combine multiple QTc prolonging agents, including bedaquiline and delamanid, which act partly through hERG potassium channel binding. Promethazine, a first-generation antihistamine used for nausea during TB therapy, shares this mechanism. Whether adjunctive promethazine further raises the risk of clinically relevant QTc prolongation in this setting is unclear. Methods: We conducted secondary analyses from a prospective observational cohort study of patients ≥15 years in Lesotho who received a 9- to 12-month all-oral regimen (bedaquiline, linezolid, levofloxacin, clofazimine, delamanid) for pulmonary MDR/RR-TB. We modelled time-varying promethazine exposure using the Andersen-Gill formulation of Cox regression, with time-to-first grade ≥3 (>500 ms) QTc event as the outcome of interest. We conducted comparator analyses with time-varying exposure to metoclopramide, ondansetron, and episodes of nausea, dizziness, and vomiting. Results: Among 247 participants (median age 41, 63.2% living with HIV), 62 (25.1%) received promethazine. Grade ≥3 QTc prolongation occurred in 10 (4.0%). Incident clinically significant QTc prolongation was higher during promethazine-exposed than unexposed periods (7.4 versus 1.3 per 10 000 person-days; HR 7.0, 95% CI: 1.4–35.3). No comparable elevation was seen in analyses of exposure to metoclopramide (HR 1.0, 95% CI: 0.3–3.6), ondansetron, or episodes of nausea, dizziness, or vomiting (HR 1.5, 95% CI: 0.3–6.9). Conclusions: Promethazine use was associated with increased risk of clinically relevant QTc prolongation within a QTc-burdened all-oral MDR/RR-TB regimen. These findings provide preliminary evidence that clinicians may consider when selecting anti-emetics as part of MDR/RR-TB therapy with a shortened all-oral regimen and highlight the importance of evaluating adjunctive medications in DR-TB care.
- Open Access
- 12 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation
Background: Peripheral neuropathy frequently leads to linezolid dose reductions or interruptions during multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) treatment. The implications of these modifications on treatment success are uncertain. Methods: We conducted a target trial emulation using the endTB Observational Study among individuals who developed non-severe peripheral neuropathy while receiving linezolid 600 mg daily within 6 months of initiating an individualized MDR/RR-TB regimen. We examined three linezolid management strategies: immediate change (i.e., dose reduction, temporary interruption, discontinuation) within Weeks 1–7 after peripheral neuropathy onset, deferred change within Weeks 8–26, and no change (i.e., continuing linezolid 600 mg daily) during Weeks 1–26. To emulate the per-protocol analysis of a trial, we used an approach involving cloning and censoring participant data, and applying inverse probability of censoring weights. Results: Among 303 eligible participants from 12 countries, peripheral neuropathy occurred a median of 11 weeks (interquartile range: 4–18) after treatment initiation. Weighted, standardized probabilities of treatment success were 84.7% (95% CI: 69.2%, 92.9%) for immediate change, 78.9% (95% CI: 65.9%, 87.1%) for deferred change, and 85.2% (95% CI: 80.5%, 89.1%) for no change. Compared with no change, treatment success ratios were 0.99 (95% CI: 0.83, 1.11) for immediate change and 0.93 (95% CI: 0.78, 1.01) for deferred change. Conclusions: We did not find evidence of a substantial negative impact of immediate modification to linezolid on MDR/RR-TB treatment success. Our results support the clinical practice of cautiously adjusting linezolid when needed to manage non-severe peripheral neuropathy.
- 12 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessComparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation
Background: Peripheral neuropathy frequently leads to linezolid dose reductions or interruptions during multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) treatment. The implications of these modifications on treatment success are uncertain. Methods: We conducted a target trial emulation using the endTB Observational Study among individuals who developed non-severe peripheral neuropathy while receiving linezolid 600 mg daily within 6 months of initiating an individualized MDR/RR-TB regimen. We examined three linezolid management strategies: immediate change (i.e., dose reduction, temporary interruption, discontinuation) within Weeks 1–7 after peripheral neuropathy onset, deferred change within Weeks 8–26, and no change (i.e., continuing linezolid 600 mg daily) during Weeks 1–26. To emulate the per-protocol analysis of a trial, we used an approach involving cloning and censoring participant data, and applying inverse probability of censoring weights. Results: Among 303 eligible participants from 12 countries, peripheral neuropathy occurred a median of 11 weeks (interquartile range: 4–18) after treatment initiation. Weighted, standardized probabilities of treatment success were 84.7% (95% CI: 69.2%, 92.9%) for immediate change, 78.9% (95% CI: 65.9%, 87.1%) for deferred change, and 85.2% (95% CI: 80.5%, 89.1%) for no change. Compared with no change, treatment success ratios were 0.99 (95% CI: 0.83, 1.11) for immediate change and 0.93 (95% CI: 0.78, 1.01) for deferred change. Conclusions: We did not find evidence of a substantial negative impact of immediate modification to linezolid on MDR/RR-TB treatment success. Our results support the clinical practice of cautiously adjusting linezolid when needed to manage non-severe peripheral neuropathy.
- Open Access
- 3 June 2026
- Published by Elsevier in The Lancet Global Health
- Vol. 14 (7) , 103978
Immortal time bias in observational analyses of linezolid interruption and rechallenge
- 3 June 2026
- Published by Elsevier in The Lancet Global Health
- Vol. 14 (7) , 103978
Open AccessImmortal time bias in observational analyses of linezolid interruption and rechallenge
- Open Access
Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation
Background: Peripheral neuropathy frequently leads to linezolid dose reductions or interruptions during multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) treatment. The implications of these modifications on treatment success are uncertain. Methods: We conducted a target trial emulation using the endTB Observational Study among individuals who developed non-severe peripheral neuropathy while receiving linezolid 600 mg daily within 6 months of initiating an individualized MDR/RR-TB regimen. We examined three linezolid management strategies: immediate change (i.e., dose reduction, temporary interruption, discontinuation) within Weeks 1-7 after peripheral neuropathy onset, deferred change within Weeks 8-26, and no change (i.e., continuing linezolid 600 mg daily) during Weeks 1-26. To emulate the per-protocol analysis of a trial, we used an approach involving cloning and censoring participant data, and applying inverse probability of censoring weights. Results: Among 303 eligible participants from 12 countries, peripheral neuropathy occurred a median of 11 weeks (interquartile range: 4-18) after treatment initiation. Weighted, standardized probabilities of treatment success were 84.7% (95% CI: 69.2%, 92.9%) for immediate change, 78.9% (95% CI: 65.9%, 87.1%) for deferred change, and 85.2% (95% CI: 80.5%, 89.1%) for no change. Compared with no change, treatment success ratios were 0.99 (95% CI: 0.83, 1.11) for immediate change and 0.93 (95% CI: 0.78, 1.01) for deferred change. Conclusions: We did not find evidence of a substantial negative impact of immediate modification to linezolid on MDR/RR-TB treatment success. Our results support the clinical practice of cautiously adjusting linezolid when needed to manage non-severe peripheral neuropathy.
Open AccessComparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation
Background: Peripheral neuropathy frequently leads to linezolid dose reductions or interruptions during multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) treatment. The implications of these modifications on treatment success are uncertain. Methods: We conducted a target trial emulation using the endTB Observational Study among individuals who developed non-severe peripheral neuropathy while receiving linezolid 600 mg daily within 6 months of initiating an individualized MDR/RR-TB regimen. We examined three linezolid management strategies: immediate change (i.e., dose reduction, temporary interruption, discontinuation) within Weeks 1-7 after peripheral neuropathy onset, deferred change within Weeks 8-26, and no change (i.e., continuing linezolid 600 mg daily) during Weeks 1-26. To emulate the per-protocol analysis of a trial, we used an approach involving cloning and censoring participant data, and applying inverse probability of censoring weights. Results: Among 303 eligible participants from 12 countries, peripheral neuropathy occurred a median of 11 weeks (interquartile range: 4-18) after treatment initiation. Weighted, standardized probabilities of treatment success were 84.7% (95% CI: 69.2%, 92.9%) for immediate change, 78.9% (95% CI: 65.9%, 87.1%) for deferred change, and 85.2% (95% CI: 80.5%, 89.1%) for no change. Compared with no change, treatment success ratios were 0.99 (95% CI: 0.83, 1.11) for immediate change and 0.93 (95% CI: 0.78, 1.01) for deferred change. Conclusions: We did not find evidence of a substantial negative impact of immediate modification to linezolid on MDR/RR-TB treatment success. Our results support the clinical practice of cautiously adjusting linezolid when needed to manage non-severe peripheral neuropathy.
- Open Access
- 2 February 2026
- Published by Elsevier in SSRN Electronic Journal
Using Causal Frameworks to Reduce Bias in Observational TB Research: A Comparison of Model-Building Approaches
Background: Observational studies investigating causal (aetiological) questions often address confounding bias using data-driven predictive models where variables are selected regardless of their causal role, challenging interpretation. We compared the estimated effect of HIV co-infection on end-of-treatment outcomes among people with multidrug/rifampicin-resistant tuberculosis using a causal framework model and a data-driven predictive model.Methods: The causal framework guided confounder adjustment. Results were compared with models that applied alternative variable selection strategies (based on p-values and change-in-estimate), which do not draw on domain knowledge to identify relevant variables.Findings: The model informed by a causal diagram indicated that people living with HIV had a 31% lower probability of achieving a successful outcome compared to those without HIV (adjusted risk ratio [aRR] 0.69, 95% CI: 0.41 – 0.98). In contrast, data-driven models produced attenuated associations (aRR 0.78, 95% CI 0.50 – 1.06 and aRR 0.80, 95% CI 0.51 – 1.09 for the p-value and change-in-estimate strategies, respectively), reflecting omission of key confounders, and inappropriate inclusion of mediators and colliders.Interpretation: When the research question is aetiological, using a causal approach to guide variable selection ensures proper adjustment, improves interpretability, and establishes a stronger foundation for future observational research.
- 2 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessUsing Causal Frameworks to Reduce Bias in Observational TB Research: A Comparison of Model-Building Approaches
Background: Observational studies investigating causal (aetiological) questions often address confounding bias using data-driven predictive models where variables are selected regardless of their causal role, challenging interpretation. We compared the estimated effect of HIV co-infection on end-of-treatment outcomes among people with multidrug/rifampicin-resistant tuberculosis using a causal framework model and a data-driven predictive model.Methods: The causal framework guided confounder adjustment. Results were compared with models that applied alternative variable selection strategies (based on p-values and change-in-estimate), which do not draw on domain knowledge to identify relevant variables.Findings: The model informed by a causal diagram indicated that people living with HIV had a 31% lower probability of achieving a successful outcome compared to those without HIV (adjusted risk ratio [aRR] 0.69, 95% CI: 0.41 – 0.98). In contrast, data-driven models produced attenuated associations (aRR 0.78, 95% CI 0.50 – 1.06 and aRR 0.80, 95% CI 0.51 – 1.09 for the p-value and change-in-estimate strategies, respectively), reflecting omission of key confounders, and inappropriate inclusion of mediators and colliders.Interpretation: When the research question is aetiological, using a causal approach to guide variable selection ensures proper adjustment, improves interpretability, and establishes a stronger foundation for future observational research.
- Open Access
- 25 December 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003777
Effect of smoking on drug-resistant tuberculosis treatment outcomes and potential mechanistic pathways: a multicountry cohort study
Background: People who smoke are at increased risk of unfavourable tuberculosis treatment outcomes compared with those who do not, but the pathways that explain this disparity are unclear. Objective: To estimate the difference in a successful end-of-treatment outcome by smoking status among people with multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) and to examine if this difference changes if people who smoked had the same retention in treatment as those who did not smoke. Design and methods: Using data from the prospective endTB Observational Study, we estimated the difference in treatment success by cigarette smoking status, adjusting for baseline confounders including demographics, social history and comorbidities. To examine how this difference changed if everyone was retained in treatment, we censored participants who were lost to follow-up and applied inverse probability of censoring weights to simulate this scenario. Results: Among 1786 participants in 12 countries, 539 (30.2%) reported smoking at least one cigarette daily. People who smoked were more frequently found in post-Soviet countries and had a complex social history (eg, incarceration and substance use) and infectious comorbidities (eg, hepatitis C). At the end of treatment, 73.5% of people who smoked and 80.3% of people who did not smoke had treatment success (risk difference in percentage points: −6.8, 95% CI −11.1 to –2.6). After adjusting for baseline confounders, the risk difference was similar (−5.2 percentage points), but the 95% CI was less precise (−14.1 to 3.2). When simulating a scenario in which everyone was retained in treatment, the risk difference was attenuated (−1.9 percentage points; 95% CI −11.1 to 4.7). Conclusion: People who smoked had a lower frequency of MDR/RR-TB treatment success than those who did not smoke. Eliminating loss to follow-up reduced this difference by smoking status, suggesting that pathways related to retention in treatment were a major driver of this disparity.
- 25 December 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e003777
Open AccessEffect of smoking on drug-resistant tuberculosis treatment outcomes and potential mechanistic pathways: a multicountry cohort study
Background: People who smoke are at increased risk of unfavourable tuberculosis treatment outcomes compared with those who do not, but the pathways that explain this disparity are unclear. Objective: To estimate the difference in a successful end-of-treatment outcome by smoking status among people with multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) and to examine if this difference changes if people who smoked had the same retention in treatment as those who did not smoke. Design and methods: Using data from the prospective endTB Observational Study, we estimated the difference in treatment success by cigarette smoking status, adjusting for baseline confounders including demographics, social history and comorbidities. To examine how this difference changed if everyone was retained in treatment, we censored participants who were lost to follow-up and applied inverse probability of censoring weights to simulate this scenario. Results: Among 1786 participants in 12 countries, 539 (30.2%) reported smoking at least one cigarette daily. People who smoked were more frequently found in post-Soviet countries and had a complex social history (eg, incarceration and substance use) and infectious comorbidities (eg, hepatitis C). At the end of treatment, 73.5% of people who smoked and 80.3% of people who did not smoke had treatment success (risk difference in percentage points: −6.8, 95% CI −11.1 to –2.6). After adjusting for baseline confounders, the risk difference was similar (−5.2 percentage points), but the 95% CI was less precise (−14.1 to 3.2). When simulating a scenario in which everyone was retained in treatment, the risk difference was attenuated (−1.9 percentage points; 95% CI −11.1 to 4.7). Conclusion: People who smoked had a lower frequency of MDR/RR-TB treatment success than those who did not smoke. Eliminating loss to follow-up reduced this difference by smoking status, suggesting that pathways related to retention in treatment were a major driver of this disparity.
- Open Access
- 23 October 2025
- Published by AOSIS in Journal of Public Health in Africa
- Vol. 16 (1) , 15
Knowledge, attitudes and practices related to SARS-CoV-2 prevention in Kenya
Background: Knowledge, attitudes, and practices (KAPs) regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) non-pharmaceutical interventions (NPIs) may differ among populations with health vulnerabilities. Aim: To examine COVID-19 KAPs among Kenyan adolescents and adults with behavioural vulnerability to HIV. Setting: This study was conducted in Kericho and Homa Bay, Kenya. Methods: From December 2021 to April 2023, we enrolled participants without HIV aged 14-55 years who reported recent sexually transmitted infection, injection drug use, transactional sex, condomless sex, and/or anal sex with males. A self-administered questionnaire captured sociodemographic data and KAPs. Multivariable robust Poisson regression with purposeful variable selection was used to estimate prevalence ratios (PRs) and 95% confidence intervals (CIs) for factors associated with NPI practices. Results: Among 399 participants (median age 22 years [interquartile range 19–24]), 317 (79.4%) were female. Participants during the Omicron-variant wave were less likely to meet outdoors (PR = 0.85 [95% CI: 0.73–0.98]), reduce shopping (PR = 0.83 [95% CI: 0.73–0.96], and avoid crowds (PR = 0.81 [95% CI: 0.71-0.93]). Believing that mask-wearing prevents SARS-CoV-2 was associated with less meeting outdoors (PR = 0.44 [95% CI: 0.27–0.73]) and reducing shopping (PR = 0.48 [95% CI: 0.31–0.76]), while believing that handwashing prevents SARS-CoV-2 was associated with less crowd avoidance (PR = 0.73 [95% CI: 0.60–0.89]). Perceiving widespread community face mask use was associated with reduced shopping (PR = 1.12 [95% CI: 1.02–1.23]). Conclusion: Belief in personal NPIs (mask-wearing and handwashing) was associated with decreased practice of social NPIs (meeting outdoors, reducing shopping, and avoiding crowds). Contribution: Future public health strategies for pandemic response should anticipate risk compensation.
- 23 October 2025
- Published by AOSIS in Journal of Public Health in Africa
- Vol. 16 (1) , 15
Open AccessKnowledge, attitudes and practices related to SARS-CoV-2 prevention in Kenya
Background: Knowledge, attitudes, and practices (KAPs) regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) non-pharmaceutical interventions (NPIs) may differ among populations with health vulnerabilities. Aim: To examine COVID-19 KAPs among Kenyan adolescents and adults with behavioural vulnerability to HIV. Setting: This study was conducted in Kericho and Homa Bay, Kenya. Methods: From December 2021 to April 2023, we enrolled participants without HIV aged 14-55 years who reported recent sexually transmitted infection, injection drug use, transactional sex, condomless sex, and/or anal sex with males. A self-administered questionnaire captured sociodemographic data and KAPs. Multivariable robust Poisson regression with purposeful variable selection was used to estimate prevalence ratios (PRs) and 95% confidence intervals (CIs) for factors associated with NPI practices. Results: Among 399 participants (median age 22 years [interquartile range 19–24]), 317 (79.4%) were female. Participants during the Omicron-variant wave were less likely to meet outdoors (PR = 0.85 [95% CI: 0.73–0.98]), reduce shopping (PR = 0.83 [95% CI: 0.73–0.96], and avoid crowds (PR = 0.81 [95% CI: 0.71-0.93]). Believing that mask-wearing prevents SARS-CoV-2 was associated with less meeting outdoors (PR = 0.44 [95% CI: 0.27–0.73]) and reducing shopping (PR = 0.48 [95% CI: 0.31–0.76]), while believing that handwashing prevents SARS-CoV-2 was associated with less crowd avoidance (PR = 0.73 [95% CI: 0.60–0.89]). Perceiving widespread community face mask use was associated with reduced shopping (PR = 1.12 [95% CI: 1.02–1.23]). Conclusion: Belief in personal NPIs (mask-wearing and handwashing) was associated with decreased practice of social NPIs (meeting outdoors, reducing shopping, and avoiding crowds). Contribution: Future public health strategies for pandemic response should anticipate risk compensation.
- Open Access
Effect of smoking on drug-resistant tuberculosis treatment outcomes and potential mechanistic pathways: A multicountry cohort study
Background: People who smoke are at increased risk of unfavorable tuberculosis treatment outcomes compared with those who do not, but the pathways that explain this disparity are unclear. Objective: To estimate the difference in a successful end-of-treatment outcome by smoking status among people with multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) and to examine if this difference changes if people who smoked had the same retention in treatment as those who did not smoke. Design and methods: Using data from the prospective endTB Observational Study, we estimated the difference in treatment success by cigarette smoking status, adjusting for baseline confounders including demographics, social history, and comorbidities. To examine how this difference changed if everyone was retained in treatment, we censored participants who were lost to follow-up and applied inverse probability of censoring weights to simulate this scenario. Results: Among 1786 participants in 12 countries, 539 (30.2%) reported smoking at least 1 cigarette daily. People who smoked were more frequently in post-Soviet countries, and had a complex social history (e.g., incarceration and substance use) and infectious comorbidities (e.g., hepatitis C). At the end of treatment, 73.5% of people who smoked and 80.3% of people who did not smoke had treatment success (risk difference in percentage points: -6.8, 95% confidence interval [CI]: -11.1, -2.6). After adjusting for baseline confounders, the risk difference was similar (-5.2 percentage points) but the 95% CI was less precise (-14.1, 3.2). When simulating a scenario in which everyone was retained in treatment, the risk difference was attenuated (-1.9 percentage points; 95% CI: -11.1, 4.7). Conclusion: People who smoked had a lower frequency of MDR/RR-TB treatment success than those who did not smoke. Eliminating loss to follow-up reduced this difference by smoking status, suggesting that pathways related to retention in treatment were a major driver of this disparity. What is already known on this topic: Most observational research supports that cigarette smoking negatively impacts TB treatment outcomes, but it is unclear why. What this study adds: People who smoked had a lower frequency of MDR/RR-TB treatment success than those who did not smoke. Eliminating loss to follow-up attenuated this difference. How this study might affect research, practice, or policy: Implementing interventions that address causes of loss to follow-up, in addition to smoking cessation services, could improve MDR/RR-TB treatment outcomes among people who smoke.
Open AccessEffect of smoking on drug-resistant tuberculosis treatment outcomes and potential mechanistic pathways: A multicountry cohort study
Background: People who smoke are at increased risk of unfavorable tuberculosis treatment outcomes compared with those who do not, but the pathways that explain this disparity are unclear. Objective: To estimate the difference in a successful end-of-treatment outcome by smoking status among people with multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) and to examine if this difference changes if people who smoked had the same retention in treatment as those who did not smoke. Design and methods: Using data from the prospective endTB Observational Study, we estimated the difference in treatment success by cigarette smoking status, adjusting for baseline confounders including demographics, social history, and comorbidities. To examine how this difference changed if everyone was retained in treatment, we censored participants who were lost to follow-up and applied inverse probability of censoring weights to simulate this scenario. Results: Among 1786 participants in 12 countries, 539 (30.2%) reported smoking at least 1 cigarette daily. People who smoked were more frequently in post-Soviet countries, and had a complex social history (e.g., incarceration and substance use) and infectious comorbidities (e.g., hepatitis C). At the end of treatment, 73.5% of people who smoked and 80.3% of people who did not smoke had treatment success (risk difference in percentage points: -6.8, 95% confidence interval [CI]: -11.1, -2.6). After adjusting for baseline confounders, the risk difference was similar (-5.2 percentage points) but the 95% CI was less precise (-14.1, 3.2). When simulating a scenario in which everyone was retained in treatment, the risk difference was attenuated (-1.9 percentage points; 95% CI: -11.1, 4.7). Conclusion: People who smoked had a lower frequency of MDR/RR-TB treatment success than those who did not smoke. Eliminating loss to follow-up reduced this difference by smoking status, suggesting that pathways related to retention in treatment were a major driver of this disparity. What is already known on this topic: Most observational research supports that cigarette smoking negatively impacts TB treatment outcomes, but it is unclear why. What this study adds: People who smoked had a lower frequency of MDR/RR-TB treatment success than those who did not smoke. Eliminating loss to follow-up attenuated this difference. How this study might affect research, practice, or policy: Implementing interventions that address causes of loss to follow-up, in addition to smoking cessation services, could improve MDR/RR-TB treatment outcomes among people who smoke.